A Phase IIa, Multi-center, Dose-finding Study to Evaluate Safety and Efficacy for Prevention of Oral Mucositis and PK of MIT-001 in Patients With Lymphoma or Multiple Myeloma Receiving Conditioning Chemotherapy Followed by Auto HSCT
Latest Information Update: 31 May 2024
At a glance
- Drugs MIT 001 (Primary)
- Indications Stomatitis
- Focus Therapeutic Use
- Acronyms Capella
- Sponsors MitoImmune Therapeutics
Most Recent Events
- 28 May 2024 Planned End Date changed from 30 Apr 2024 to 30 Dec 2024.
- 28 May 2024 Planned primary completion date changed from 31 Oct 2023 to 30 Jun 2024.
- 28 May 2024 Status changed from recruiting to active, no longer recruiting.